001     165578
005     20240611120548.0
024 7 _ |a 10.1038/s41586-022-05440-3
|2 doi
024 7 _ |a pmid:36385530
|2 pmid
024 7 _ |a pmc:PMC9712113
|2 pmc
024 7 _ |a 0028-0836
|2 ISSN
024 7 _ |a 1476-4687
|2 ISSN
024 7 _ |a altmetric:138511969
|2 altmetric
037 _ _ |a DZNE-2022-01718
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Wagner, Jessica
|0 P:(DE-2719)2812193
|b 0
|e First author
245 _ _ |a Medin co-aggregates with vascular amyloid-β in Alzheimer's disease.
260 _ _ |a London [u.a.]
|c 2022
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718022178_5323
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Aggregates of medin amyloid (a fragment of the protein MFG-E8, also known as lactadherin) are found in the vasculature of almost all humans over 50 years of age1,2, making it the most common amyloid currently known. We recently reported that medin also aggregates in blood vessels of ageing wild-type mice, causing cerebrovascular dysfunction3. Here we demonstrate in amyloid-β precursor protein (APP) transgenic mice and in patients with Alzheimer's disease that medin co-localizes with vascular amyloid-β deposits, and that in mice, medin deficiency reduces vascular amyloid-β deposition by half. Moreover, in both the mouse and human brain, MFG-E8 is highly enriched in the vasculature and both MFG-E8 and medin levels increase with the severity of vascular amyloid-β burden. Additionally, analysing data from 566 individuals in the ROSMAP cohort, we find that patients with Alzheimer's disease have higher MFGE8 expression levels, which are attributable to vascular cells and are associated with increased measures of cognitive decline, independent of plaque and tau pathology. Mechanistically, we demonstrate that medin interacts directly with amyloid-β to promote its aggregation, as medin forms heterologous fibrils with amyloid-β, affects amyloid-β fibril structure, and cross-seeds amyloid-β aggregation both in vitro and in vivo. Thus, medin could be a therapeutic target for prevention of vascular damage and cognitive decline resulting from amyloid-β deposition in the blood vessels of the brain.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Protein Precursor
|2 NLM Chemicals
650 _ 7 |a Serum Amyloid A Protein
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Cognitive Dysfunction
|2 MeSH
650 _ 2 |a Plaque, Amyloid
|2 MeSH
650 _ 2 |a Amyloid beta-Protein Precursor
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Serum Amyloid A Protein
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Protein Precursor: metabolism
|2 MeSH
650 _ 2 |a Plaque, Amyloid: metabolism
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
700 1 _ |a Degenhardt, Karoline
|0 P:(DE-2719)2810939
|b 1
|e First author
700 1 _ |a Veit, Marleen
|0 P:(DE-2719)9001638
|b 2
700 1 _ |a Louros, Nikolaos
|0 0000-0002-4030-1022
|b 3
700 1 _ |a Konstantoulea, Katerina
|0 0000-0002-0960-6274
|b 4
700 1 _ |a Skodras, Angelos
|0 P:(DE-2719)2810430
|b 5
700 1 _ |a Wild, Katleen
|0 P:(DE-2719)2811762
|b 6
700 1 _ |a Liu, Ping
|0 P:(DE-2719)9002490
|b 7
|u dzne
700 1 _ |a Obermüller, Ulrike
|0 P:(DE-2719)2814201
|b 8
700 1 _ |a Bansal, Vikas
|0 P:(DE-2719)2812055
|b 9
700 1 _ |a Dalmia, Anupriya
|0 P:(DE-2719)2812478
|b 10
700 1 _ |a Häsler, Lisa M
|0 P:(DE-2719)2811581
|b 11
700 1 _ |a Lambert, Marius
|0 P:(DE-2719)2810762
|b 12
700 1 _ |a De Vleeschouwer, Matthias
|b 13
700 1 _ |a Davies, Hannah A
|b 14
700 1 _ |a Madine, Jillian
|0 0000-0001-9963-5871
|b 15
700 1 _ |a Kronenberg-Versteeg, Deborah
|0 P:(DE-2719)9001451
|b 16
700 1 _ |a Feederle, Regina
|0 P:(DE-2719)2812867
|b 17
700 1 _ |a Del Turco, Domenico
|b 18
700 1 _ |a Nilsson, K Peter R
|b 19
700 1 _ |a Lashley, Tammaryn
|b 20
700 1 _ |a Deller, Thomas
|b 21
700 1 _ |a Gearing, Marla
|b 22
700 1 _ |a Walker, Lary C.
|0 P:(DE-2719)9000947
|b 23
700 1 _ |a Heutink, Peter
|0 P:(DE-2719)2810728
|b 24
700 1 _ |a Rousseau, Frederic
|0 0000-0002-9189-7399
|b 25
700 1 _ |a Schymkowitz, Joost
|b 26
700 1 _ |a Jucker, Mathias
|0 P:(DE-2719)2000010
|b 27
700 1 _ |a Neher, Jonas
|0 P:(DE-2719)2811021
|b 28
|e Last author
773 _ _ |a 10.1038/s41586-022-05440-3
|g Vol. 612, no. 7938, p. 123 - 131
|0 PERI:(DE-600)1413423-8
|n 7938
|p 123 - 131
|t Nature
|v 612
|y 2022
|x 0028-0836
856 4 _ |u https://pub.dzne.de/record/165578/files/DZNE-2022-01718.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/165578/files/DZNE-2022-01718.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:165578
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812193
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810939
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001638
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810430
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811762
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9002490
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)2814201
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812478
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811581
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810762
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)9001451
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2812867
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)9000947
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2810728
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2000010
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811021
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b NATURE : 2021
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2022-11-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NATURE : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
920 1 _ |0 I:(DE-2719)1210012
|k AG Neher
|l Neuroimmunology and Neurodegenerative Disease
|x 0
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 1
920 1 _ |0 I:(DE-2719)1210002
|k AG Heutink
|l Genome Biology of Neurodegenerative Diseases
|x 2
920 1 _ |0 I:(DE-2719)1140004
|k AG Feederle
|l Monoclonal Antibodies
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210012
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1210002
980 _ _ |a I:(DE-2719)1140004
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21